Semaglutide
Semaglutide is not yet approved for reducing alcohol use. However, with the increased use of these medications for diabetes and weight loss it is becoming evident that this medication reduces alcohol cravings in addition to food cravings. Rather than me enumerate the information out there on this subject, just Google ‘Semaglutide and alcohol”. You will find dozens of articles supporting the use of Semaglutide to reduce alcohol use. Though no “double blinded peer review studies” (the gold standard in medical research) have been published on this subject, several are in process. There are many case studies series, anecdotal results of a small number of patients, affirming significant alcohol use reduction. Numerous animal studies (mostly with rats) also confirm the mediations likely efficacy.
As an aside, my comments about Semaglutide also generally apply to other “GLP-1” medications used to treat obesity such as Tirzepatide (Manjouro, Zepbound), Liraglutide (Saxenda) and others.
And then I have my personal clinical experience. I have treated hundreds of patients with Semaglutide for the indications of diabetes and/or obesity, and the result related to alcohol use reduction is clear to me. Nearly universally, alcohol use is significantly reduced in those who previously reported they were drinking “too much”. And it is also reduced even in those who did not have any issues with alcohol. Patients, along with their reduced hunger on these meds, indicate little or no desire for alcohol. I have had patents drinking too much (for example 30 drinks or more a week) who routinely cut their drinking in more than half, or even stopped drinking. And I have had many patients who were drinking in the acceptable range (15 drinks a week for men and 7 drinks a week for women) who all but eliminated or did eliminate their alcohol use altogether.
BUT IF NOT YET FDA APPROVED FOR ALCOHOL USE DISORDER,
CAN SEMAGLUTIDE BE PRESCRIBED FOR ITS TREATMENT?
The answer is “yes and no”. If a person uses too much alcohol, but also meets the diabetic or Body Mass Index (BMI) obesity/ overweight criteria for Semaglutide use per the FDA criteria, they may be prescribed the medication. It is being prescribed for the FDA-approved indication, with the knowledge of both the physician and the patient that it will also result in lower alcohol intake. Though “off label” use is common (prescribing a medication for a use that is not FDA approved for), I do not know any medical providers who are prescribing this medication for patients not meeting diabetic or Body Mass Index criteria. However, I think this will become common in the future, once some peer review studies proving the effectiveness of this therapeutic modality for alcohol use disorder have been published.
I am only prescribing Semaglutide to help patents reduce alcohol use. . . so long as they meet one of the other FDA criteria.
|